Intriguingly, the selective GR modulators (SGRMs) C134 and C335 were shown to reduce MCF-7 ESR1 mutant primary tumor growth by decreasing the expression of CCND1 (Tonsing-Carter et al, 2019). Here, NR3C1 is linked to neoplasm.